Search - tctmd.com

Displaying 401 - 420 of 438

Sort: Relevancy | Date

Presentation TCT 2012

The New Fourth-Generation WATCHMAN (BSC-Atritech): Device Design and Results of the EVOLVE Trial

Presenter: Vivek Reddy

October 23, 2012

Presentation TCT 2012

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

Presenter: Saibal Kar

October 23, 2012

Presentation TCT 2012

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

Presenter: Horst Sievert

October 23, 2012

Presentation TCT 2012

Case Presentation: A Complicated WATCHMAN Case

Presenter: Horst Sievert

October 23, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Daily News

Un Nuevo Dispositivo Resulta Prometedor para el Cierre Seguro y Eficaz del AAI

Yael L. Maxwell

October 12, 2012

News Daily News

Novel Device Shows Promise for Safe, Effective LAA Closure

Yael L. Maxwell

October 12, 2012

News Daily News

Watchman Device for LAA Closure Provides Net Clinical Benefit vs. Warfarin in A-fib Patients

September 27, 2012

News Daily News

El Dispositivo Watchman para el Cierre del AAI Ofrece Beneficios Clínicos Netos comparado con la Warfarina en Pacientes con FA

September 27, 2012

News Industry News

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

August 26, 2012

News Industry News

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

July 02, 2012

Presentation TVT 2012

The Watchman Clinical Studies Program (Warfarin Eligible): Perspectives, New Insights, and Future Directions

Presenter: Saibal Kar

June 05, 2012

Presentation TVT 2012

Taped Case Study: The Watchman Procedure(2)

Presenter: Saibal Kar

June 05, 2012

Presentation TVT 2012

ASAP Results: The Watchman in Warfarin Ineligible Patients

Presenter: Shephal Doshi

June 05, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

June 01, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

March 20, 2012

News Daily News

Lack of Complete Seal with Watchman Device Common, But No Cause for Alarm

Jason Kahn

March 05, 2012

Advertisement

The New Fourth-Generation WATCHMAN (BSC-Atritech): Device Design and Results of the EVOLVE Trial

TCT-84. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients 75 Years or Greater; A Sub-Analysis of the PROTECT AF Study

TCT-83. Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients with Contraindication to Oral Anticoagulation: the “Aspirin Plavix Registry” (ASAP)

Case Presentation: A Complicated WATCHMAN Case

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Un Nuevo Dispositivo Resulta Prometedor para el Cierre Seguro y Eficaz del AAI

Novel Device Shows Promise for Safe, Effective LAA Closure

Watchman Device for LAA Closure Provides Net Clinical Benefit vs. Warfarin in A-fib Patients

El Dispositivo Watchman para el Cierre del AAI Ofrece Beneficios Clínicos Netos comparado con la Warfarina en Pacientes con FA

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

The Watchman Clinical Studies Program (Warfarin Eligible): Perspectives, New Insights, and Future Directions

Taped Case Study: The Watchman Procedure(2)

ASAP Results: The Watchman in Warfarin Ineligible Patients

Watchman Works Just as Well Without Warfarin-Protected Transition

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

Lack of Complete Seal with Watchman Device Common, But No Cause for Alarm

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content